ReviewFrontiers in immunology2026
The role of USP19 in human diseases: from molecular function to clinical relevance.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
USP19 is an important member of the ubiquitin-specific protease (USP) subfamily within the deubiquitinase superfamily. It primarily regulates protein stability, subcellular localization, and signaling pathway activity by specifically removing ubiquitin modifications from substrate proteins, and it is widely involved in the regulation of cellular physiological homeostasis and various pathological processes. USP19 shows aberrant expression and functional dysregulation in multiple malignancies, participating in the regulation of tumor proliferation, metastasis, apoptosis, immune evasion, and chemoresistance by targeting key molecules such as c-Myc, p53, PD-L1, MGMT, and PARK7. Additionally, it regulates inflammatory responses, immune responses, viral infections, and non-neoplastic diseases such as liver injury, fibrosis, and neurodegeneration. Mechanistic research on USP19 has expanded considerably, and its key substrates and signaling pathways have become potential targets for pharmacological intervention; small-molecule modulators and the development of targeted strategies remain at the preclinical stage. USP19 displays disease-specific expression patterns across different tissues: it is aberrantly overexpressed in most tumors and is closely associated with poor patient prognosis, whereas in certain tumors and non-neoplastic diseases it shows low expression or a protective upregulation. This article systematically summarizes the molecular characteristics, physiological functions, disease-related mechanisms, and clinical translational potential of USP19, to provide a comprehensive overview for its use as a novel diagnostic biomarker, prognostic stratification tool, treatment response predictor, and direct drug target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.